COMPANY · NIPC 500207879

BRISTOL-MYERS SQUIBB PORTUGAL

This page shows the public contracts the company has signed, which bodies gave them, and who it competed against.

Portal BASE records €4,012,969.70 across 98 contracts.

Follow (RSS) · What is RSS?

Identification

Company nameBRISTOL-MYERS SQUIBB PORTUGAL
NIPC500207879

None of the registers we read (GLEIF, TED and contract documents) identifies this company; the name comes from Portal BASE contracts.

Contracted money

Sums of the contract prices on Portal BASE. A contract with several buyers or municipalities counts once in each row, so rows do not add up to the total.

Contracted value by yearBars with the value contracted in each year, from 2015 to 2026. The table below gives the same values.2015: €465,913.4520152016: €1,240,241.592017: €659,384.6720172018: €679,782.892019: €334,845.5020192020: €37,326.962024: €88,966.9120242025: €316,841.552026: €189,666.182026€1,240,241.59
Contracted value by year
YearContractsContract value
201513€465,913.45
201627€1,240,241.59
201713€659,384.67
201813€679,782.89
20194€334,845.50
20201€37,326.96
20241€88,966.91
202511€316,841.55
202615€189,666.18
Contracted value by place of performance
NameContractsContract value
Almada97€3,921,463.70
Viana do Castelo1€91,506
Largest contracts
SubjectYearContract value
DASAtinib 50 mg Comp. / Atazanavir 300mg Cáps - Ajuste Directo no 112532162016€310,931.21
AQUISIÇÃO DE MEDICAMENTOSS P259-AC-2017-65 - Ajuste Directo No 111213172017€279,846.01
Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2023/304 - Medicamentos do grupo 4: sangue; 2023/305 - Medicamentos do aparelho cardiovascular; 2023/481 - Medicamentos diversos; 2023/491 - Medicamentos do foro oncológic2025€260,208.73
Medicamentos antirretrovíricos para o tratamento da infeção por VIH - ATAZANAVIR 300MG CÁPS. (P259-2018-8)2018€159,645.06
Medicamentos do Foro Oncológico para 2018 - CPA 2015/62018€140,320.76

Who they competed with

In 3 contracts with a list of competitors, the company took part and was awarded 3 (100%).

Companies with the most procedures in common
CompanyProcedures in common
BRISTOL-MYERS SQUIB FARMAC PORTUGUESA, S.A.3
Lilly Portugal - Produtos Farmacêuticos, Lda1
Marck Sharp & Dohme, Lda1
AMGEN BIOFARMACÊUTICA, LDA.1
GILEAD SCIENCES LDA.1

The annual IMPIC file lists competitors for about 42% of contracts. Only these enter the counts, and the award share is measured on them.

Links read in contract documents

Contract documents give addresses and the names of representatives and partners, and Portal BASE and GLEIF give competitors and groups. This is what the records show; the same address or name can have simple explanations.

Links read in contract documents33 companies and 35 links. The list below gives the same content as text.BRISTOL-MYERS … (NIPC 500048193)BRISTOL-MYERS …NIPC 500063524 (NIPC 500063524)NIPC 500063524NIPC 500134960 (NIPC 500134960)NIPC 500134960NIPC 500139962 (NIPC 500139962)NIPC 500139962NIPC 500162085 (NIPC 500162085)NIPC 500162085NIPC 500162166 (NIPC 500162166)NIPC 500162166Lilly Portugal… (NIPC 500165602)Lilly Portugal…Marck Sharp & … (NIPC 500191360)Marck Sharp & …NIPC 500207879 (NIPC 500207879)NIPC 500207879NIPC 500220913 (NIPC 500220913)NIPC 500220913GILEAD SCIENCE… (NIPC 503604704)GILEAD SCIENCE…+22 in the list below

Dotted: competed in the same procedure. Dotted: same procedure.

23 more links

Investigations that mention it

No published investigation mentions this company by NIPC.